Dianthus Therapeutics, Inc. /DE/ ($DNTH)
Filing Information
| Accession Number | 0001992260-26-000004 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 14, 2026 |
| Document | View SEC Filing |
Transactions
9
Total Shares
101,490
Total Value
$3,370,634.16
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP, Head of R&D | Common Stock | โ | Mar 12, 2026 | Exercise/Conversion | 7,998 | $8.44 | $67,503.12 | 7,998 | Direct | โ | View Details | |
EVP, Head of R&D | Common Stock | โ | Mar 12, 2026 | Exercise/Conversion | 5,000 | $17.88 | $89,400.00 | 12,998 | Direct | โ | View Details | |
EVP, Head of R&D | Common Stock | โ | Mar 12, 2026 | Exercise/Conversion | 8,332 | $21.77 | $181,387.64 | 21,330 | Direct | โ | View Details | |
EVP, Head of R&D | Common Stock | โ | Mar 12, 2026 | Exercise/Conversion | 12,500 | $22.07 | $275,875.00 | 33,830 | Direct | โ | View Details | |
EVP, Head of R&D | Common Stock | โ | Mar 12, 2026 | Sale | 33,830 | $81.48 | $2,756,468.40 | 0 | Direct | โ | View Details | |
EVP, Head of R&D | Stock Option (Right to Buy) | Derivative | Mar 12, 2026 | Exercise/Conversion | 7,998 | $0.00 | $0.00 | 3,998 | Direct | โ | View Details | |
EVP, Head of R&D | Stock Option (Right to Buy) | Derivative | Mar 12, 2026 | Exercise/Conversion | 5,000 | $0.00 | $0.00 | 71,184 | Direct | โ | View Details | |
EVP, Head of R&D | Stock Option (Right to Buy) | Derivative | Mar 12, 2026 | Exercise/Conversion | 8,332 | $0.00 | $0.00 | 54,174 | Direct | โ | View Details | |
EVP, Head of R&D | Stock Option (Right to Buy) | Derivative | Mar 12, 2026 | Exercise/Conversion | 12,500 | $0.00 | $0.00 | 106,250 | Direct | โ | View Details |